BIOTRICITY INC. (BTCY): Nasdaq/NYSE listing notice — Nasdaq panel grants Biotricity continued listing subject to milestones by July 29, 2024

BIOTRICITY INC.

Panel granted listing continuation after hearing on April 9, 2024.
Conditions include increasing outstanding shares via stock offerings and convertible conversions.
Company must receive shareholder approval for certain actions.
Biotricity must regain compliance with all Nasdaq listing requirements by July 29, 2024.
Previously received delisting notice for MVLS below $35M for 30 consecutive days.

item 3.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIOTRICITY INC. received a nasdaq extension granted notice regarding market value.

Exchange: nasdaq
Notice: extension granted
Deficiency: market value

Exact text from the filing

April 23, 2024, Nasdaq notified the Company that the Panel granted its request to continue its listing on Nasdaq, subject to the Company meeting certain milestones including an increase in its outstanding shares of common stock through the issuance of shares of stock in certain stock offerings and upon the conversion of certain convertible securities, the receipt of shareholder approval of certain actions and on or before July 29, 2024, the Company regaining compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.

View on SEC.gov

Browse all listing & compliance notices →

BIOTRICITY INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-015713

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.